DK1695980T3 - Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen - Google Patents

Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen

Info

Publication number
DK1695980T3
DK1695980T3 DK06012247.0T DK06012247T DK1695980T3 DK 1695980 T3 DK1695980 T3 DK 1695980T3 DK 06012247 T DK06012247 T DK 06012247T DK 1695980 T3 DK1695980 T3 DK 1695980T3
Authority
DK
Denmark
Prior art keywords
inhibitor
tad
hpv
complex
binding pocket
Prior art date
Application number
DK06012247.0T
Other languages
English (en)
Inventor
Dale R Cameron
Jacques Archambault
Christiane Yoakim
Peter White
Yong Wang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1695980T3 publication Critical patent/DK1695980T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
DK06012247.0T 2001-07-12 2002-07-12 Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen DK1695980T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30441201P 2001-07-12 2001-07-12
EP02745024A EP1409525B1 (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket

Publications (1)

Publication Number Publication Date
DK1695980T3 true DK1695980T3 (da) 2010-08-02

Family

ID=23176405

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02745024T DK1409525T3 (da) 2001-07-12 2002-07-12 Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme
DK06012247.0T DK1695980T3 (da) 2001-07-12 2002-07-12 Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02745024T DK1409525T3 (da) 2001-07-12 2002-07-12 Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme

Country Status (14)

Country Link
US (1) US7167801B2 (da)
EP (2) EP1409525B1 (da)
JP (1) JP4602665B2 (da)
AT (2) ATE343588T1 (da)
AU (1) AU2002317122B2 (da)
CA (1) CA2448482C (da)
DE (2) DE60236114D1 (da)
DK (2) DK1409525T3 (da)
ES (2) ES2274051T3 (da)
HU (1) HUP0402069A3 (da)
IL (2) IL159150A0 (da)
MX (1) MXPA04000271A (da)
NZ (1) NZ531068A (da)
WO (1) WO2003006495A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627323A4 (en) * 2003-05-06 2008-04-09 New Century Pharmaceuticals ALBUMIN FIXATION SITES FOR EVALUATING DRUG INTERACTIONS OR THE DEVELOPMENT OF MEDICAMENTS BASED ON THEIR ALBUMIN BINDING PROPERTIES
CA2526675A1 (en) * 2003-05-26 2004-12-02 Biotie Therapies Corporation Crystalline vap-1 and uses thereof
CA2585115A1 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
US20090118301A1 (en) * 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CN112891520A (zh) * 2021-04-13 2021-06-04 吉林省国大生物工程有限公司 一种预防和控制人乳头瘤病毒感染(hpv)的活性生物蛋白的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671808B2 (en) 1991-10-11 1996-09-12 Chiron Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
US6306580B1 (en) 1998-05-01 2001-10-23 Boehringer Ingelheim (Canada) Ltd. Preparation of human papillomavirus E1 having helicase activity and method therefor
ATE235509T1 (de) 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
WO2000075182A1 (fr) * 1999-06-04 2000-12-14 Akira Kaji Cristal de proteine du facteur de recyclage ribosomique (rrf) et son application sur la base de donnees de structure tridimensionnelles provenant du cristal
GB9921938D0 (en) 1999-09-17 1999-11-17 Univ York Target for antiviral therapy
JP2003515324A (ja) * 1999-11-16 2003-05-07 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ−7を含む結晶化可能な組成物
MXPA03005479A (es) 2000-12-18 2004-05-31 Boehringer Ingelheim Ca Ltd Inhibidores del virus de papiloma.

Also Published As

Publication number Publication date
AU2002317122B2 (en) 2007-03-15
ATE465414T1 (de) 2010-05-15
DE60215658D1 (de) 2006-12-07
DE60215658T2 (de) 2007-12-27
EP1695980A2 (en) 2006-08-30
HUP0402069A3 (en) 2012-09-28
US20030082769A1 (en) 2003-05-01
ES2342309T3 (es) 2010-07-05
MXPA04000271A (es) 2005-03-07
EP1409525A2 (en) 2004-04-21
IL159150A (en) 2009-09-01
WO2003006495A2 (en) 2003-01-23
DK1409525T3 (da) 2007-02-05
IL159150A0 (en) 2004-06-01
HUP0402069A2 (hu) 2005-01-28
EP1409525B1 (en) 2006-10-25
CA2448482A1 (en) 2003-01-23
EP1695980A3 (en) 2006-09-06
CA2448482C (en) 2011-12-06
ES2274051T3 (es) 2007-05-16
WO2003006495A3 (en) 2003-07-31
JP4602665B2 (ja) 2010-12-22
EP1695980B1 (en) 2010-04-21
DE60236114D1 (de) 2010-06-02
ATE343588T1 (de) 2006-11-15
US7167801B2 (en) 2007-01-23
NZ531068A (en) 2006-06-30
JP2005512954A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE452870T1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
ATE503764T1 (de) Inhibitoren des hepatitis-c-virus
EA200400183A1 (ru) Кристаллы, содержащие соль n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида с яблочной кислотой, способы их получения и их композиции
PL373374A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
CY1109765T1 (el) Αζα- δικυκλοαλκυλο αιθερες και η χρηση τους ως αγωνιστες aλφα7-nachr
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
CY1106721T1 (el) Μεθοδος παρασκευης υψηλης καθαροτητας περινδοπριλης και ενδιαμεσα χρησιμα στη συνθεση
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
ATE431340T1 (de) N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1- piperidincarboxamid-derivate und verwandte verbindungen als cgrp-antagonisten zur behandlung von kopfschmerzen
DE50004569D1 (de) Verfahren zur gewinnung von phytosterinen durch kristallisation aus verminderten mengen methanols
DK1695980T3 (da) Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen
DE60113243D1 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates
DE60316791D1 (de) Verfahren zur aufreinigung von lanzoprazol
DE602004025386D1 (de) Neue stereoselektive synthese von benzimidazolsulfoxiden
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen
EA200601641A1 (ru) Кристаллическая композиция, содержащая оксалат эсциталопрама
ATE346029T1 (de) 3,3,4,4-tetrafluorcyclopentanverbindungen als komponenten flüssigkristalliner medien
DE60005304D1 (de) Methode zur reinigung und abtrennung von (2s,3s)- oder (2r,3s)-halohydrinderivaten
TR200503397T1 (tr) Levetirasetam'ın yeni kristal formları.
DE60312953D1 (de) Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
TR200503398T1 (tr) Trandolapril'in yeni kristal formları.
ATE441658T1 (de) Verfahren zur reinigung von 5'-geschützten 2'- deoxypurin nukleosiden